340B and Pharmaceutical Access
The 340B Drug Pricing Program supports safety net providers, such as children's hospitals, in their mission to serve low-income, uninsured and under-insured patients.
CHA Submits Drug Shortages Hearing Statement for the Record
CHA submitted a statement for a House Energy and Commerce hearing to highlight how children’s needs must be prioritized when strengthening the pediatric drug supply chain.
Fiscal Year 2023 Omnibus Summary
This detailed summary of the FY 2023 Omnibus focuses on those provisions of most interest to children’s hospitals.
VALID Act Letter
We sent a letter to Senate HELP Committee leadership to highlight the implications of the VALID Act.
Letter to FDA on Critical Shortages Affecting Pediatric Care
CHA sent a letter to the FDA asking the agency to address two critical shortages affecting children and families.
House Healthy Future Task Force Requests for Information Responses
CHA has submitted responses to several RFIs from the House Healthy Future Task Force.
COVID-19 Congressional Relief Legislation
Multiple packages for COVID-19 relief have passed to date. Read more about them here.
340B Program Talking Points
The 340B program supports children's hospitals in their mission to serve low-income, uninsured and under-insured patients.
340B Drug Pricing Program Overview
The 340B Drug Pricing Program was created by Congress to help certain health care providers purchase outpatient drugs at a reduced price.
Key Provisions of the Affordable Care Act for Children
The ACA includes important provisions to make children's health care more age-appropriate, affordable, accessible and timely.
For the Record
View CHA communications to federal policymakers such as statements for the record, RFI responses, regulatory comment letters and more.
